Dyslipidemia Pipeline Analysis Report 2026

Report Coverage

The Dyslipidemia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into dyslipidemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dyslipidemia. The dyslipidemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dyslipidemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with dyslipidemia treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dyslipidemia.

Read more about this report - Request a Free Sample

Dyslipidemia Pipeline Outlook

Dyslipidaemia is a metabolic disorder characterized by abnormal levels of lipids, including elevated low-density lipoprotein cholesterol and Lipoprotein(a) in the blood. It occurs due to genetic factors, unhealthy diet, sedentary lifestyle, and underlying metabolic conditions, increasing the risk of cardiovascular diseases such as atherosclerosis, coronary artery disease, and stroke.

Dyslipidaemia treatments focus on lipid-lowering therapies, including statins, PCSK9 inhibitors, and novel small molecules, aiming to reduce LDL-cholesterol and Lp(a) levels, thereby lowering cardiovascular risk and improving patient outcomes. In October 2024, AstraZeneca strengthened its dyslipidaemia pipeline with the pre-clinical oral Lp(a) disruptor YS2302018, licensed from CSPC Pharmaceutical Group, offering potential alone or with its PCSK9 inhibitor AZD0780 to manage cardiovascular risk effectively.

Dyslipidemia Epidemiology

Dyslipidemia continues to pose a significant global health challenge. As per Shiva Kargar et al., 2023, over 50% of the worldwide population is affected. According to the National Lipid Association, the prevalence among the Hispanic population is estimated at 65.0%, including 36.0% with elevated low-density lipoprotein cholesterol (LDL-C), 41.4% with reduced high-density lipoprotein cholesterol (HDL-C), 14.8% with high triglycerides, and 34.7% with elevated non-high-density lipoprotein cholesterol (non-HDL-C). As per Arun et al., 2024, in India, dyslipidemia affects 25%–30% of urban and 15%–20% of rural individuals, with awareness at only 15.6%. These trends highlight the urgent need for improved management and therapeutic interventions.

Dyslipidemia – Pipeline Therapeutic Assessment

Dyslipidemia Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 29%, covers a major share of the total dyslipidemia clinical trials, driven by advanced clinical trials showing strong efficacy and safety data. Phase II accounts for 26%, supported by promising mid-stage results and dose optimization studies. Phase I holds 20%, focused on initial safety and pharmacokinetics. Phase IV represents a notable share of the pipeline, reflecting post-marketing surveillance and real-world evidence. This balanced pipeline indicates continuous advancements, potentially enhancing treatment options and overall market growth.

Dyslipidemia Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the dyslipidemia pipeline analysis include small molecules, monoclonal antibodies, peptides, RNA-based therapies, and vaccines. The dyslipidemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dyslipidemia. Small molecule therapies targeting Lipoprotein(a) (Lp(a)) are gaining prominence in the dyslipidaemia drug pipeline. For instance, YS2302018, an oral Lp(a) disruptor developed by CSPC Pharmaceutical Group Ltd, is under pre-clinical investigation. It works by inhibiting the formation of Lp(a), a key low-density lipoprotein contributing to cardiovascular risk, offering potential as a standalone or combination lipid-lowering therapy.

Dyslipidemia Clinical Trials – Key Players

The EMR report for the dyslipidemia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dyslipidemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dyslipidemia clinical trials:

• Ribocure Pharmaceuticals AB
• Shanghai Argo Biopharmaceutical Co., Ltd.
• Addpharma Inc.
• CMG Pharmaceutical Co. Ltd.
• EMS
• Regeneron Pharmaceuticals
• Fujian Shengdi Pharmaceutical Co., Ltd.
• AstraZeneca
• NewAmsterdam Pharma
• Korea United Pharm. Inc.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• JW Pharmaceutical

Dyslipidemia – Emerging Drugs Profile

Key Questions Answered in the Dyslipidemia Pipeline Insight Report

• Which companies/institutions are leading the dyslipidemia drug development?
• Which company is leading the dyslipidemia pipeline development activities?
• What is the current dyslipidemia commercial assessment?
• What are the opportunities and challenges present in the dyslipidemia pipeline landscape?
• What is the efficacy and safety profile of dyslipidemia pipeline drugs?
• Which company is conducting major trials for dyslipidemia drugs?
• Which companies/institutions are involved in dyslipidemia collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in dyslipidemia?

Reasons To Buy This Report

The Dyslipidemia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for dyslipidemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into dyslipidemia collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Dyslipidemia Market

Dyslipidemia Epidemiology Forecast